alosetron has been researched along with Irritable Bowel Syndrome in 67 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 9.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "Long-term use of alosetron is effective and well-tolerated in women with chronic, diarrhea-predominant IBS, including those with more frequent urgency." | 9.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| "Alosetron 1 mg twice daily provided adequate relief of IBS pain and discomfort, and improved stool consistency in men with diarrhea-predominant IBS." | 9.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 9.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 8.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| " The goal of this review is to discern IBS treatment gaps and identify opportunities for improving its management in the primary care setting, as well as describe the most current clinical experience with alosetron, a targeted treatment for severe diarrhea-predominant IBS (IBS-D) in women." | 8.87 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. ( Bleser, S, 2011) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 8.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| "Alosetron (Lotronex, GlaxoSmithKline) is a potent and selective 5-HT(3)-receptor antagonist approved by the FDA for the treatment of women with diarrhoea-predominant irritable bowel syndrome (IBS) in whom conventional therapy has failed." | 8.82 | Alosetron and irritable bowel syndrome. ( Bradesi, S; Mayer, EA, 2003) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 7.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 7.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| "We examined the pharmacological profile of ramosetron, a 5-HT(3)-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT(3)-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide." | 7.74 | Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M, 2007) |
| " The present study examines the binding profile of platelet SERT in healthy volunteers as well as in patients with diarrhea-predominant irritable bowel syndrome (D-IBS), both before and after treatment with the 5-HT(3) receptor antagonist alosetron." | 7.72 | Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. ( Baroni, S; Bellini, M; Betti, L; Blandizzi, C; Colucci, R; Costa, F; Del Tacca, M; Giannaccini, G; Marazziti, D; Marchi, S; Mumolo, MG; Rappelli, L; Stasi, C, 2003) |
| "Alosetron vs placebo treatments, in a randomized, double-blinded, crossover manner, were studied." | 6.71 | The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. ( D'Souza, D; Diksic, M; Kersey, K; Kumakura, Y; Nakai, A, 2005) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 6.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Alosetron was not associated with any deaths." | 6.44 | Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. ( Abdollahi, M; Nikfar, S; Rahimi, R, 2008) |
| "Alosetron is a potent and highly selective serotonin 5-HT(3 )receptor antagonist that in large randomised controlled clinical trials has been shown to be clinically efficient in female patients with diarrhoea-predominant IBS." | 6.42 | Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? ( Andresen, V; Hollerbach, S, 2004) |
| " Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported." | 5.51 | Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. ( Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R, 2019) |
| "Irritable bowel syndrome affects 5-10% of North Americans, with an estimated one-third having a diarrhea-predominant form." | 5.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 5.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| "Alosetron is indicated for women with chronic, severe diarrhea-predominant IBS (d-IBS) who have not responded adequately to conventional therapy." | 5.12 | A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. ( Ameen, V; Carter, EG; Gordon, SH; Heath, AT; Krause, R; Perschy, T; West, M, 2007) |
| "The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)." | 5.11 | Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. ( Ameen, VZ; Carter, EG; Gordon, SL; Heath, AT; Lembo, AJ; Olden, KW, 2004) |
| "Alosetron 1 mg twice daily provided adequate relief of IBS pain and discomfort, and improved stool consistency in men with diarrhea-predominant IBS." | 5.11 | A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. ( Ameen, VZ; Carter, EG; Chang, L; Dukes, GE; Mayer, EA; McSorley, DJ, 2005) |
| "Long-term use of alosetron is effective and well-tolerated in women with chronic, diarrhea-predominant IBS, including those with more frequent urgency." | 5.11 | Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. ( Ameen, VZ; Carter, EG; Chey, WD; Chey, WY; Dukes, GE; Heath, AT; Northcutt, A, 2004) |
| " Direct comparison of primary endpoint results from the alosetron, rifaximin, and eluxadoline pivotal trials is not possible; however, general estimates of efficacy can be made, and these demonstrate similar and significantly greater responses to 'adequate relief' and a composite endpoint of abdominal pain/stool form for each agent compared to placebo." | 4.93 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? ( Cash, BD; Earnest, DL; Lacy, BE; Rao, T, 2016) |
| "In irritable bowel syndrome with diarrhea, tricyclic antidepressants and alosetron are associated with a significant number needed to harm compared with rifaximin." | 4.88 | Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. ( Chong, K; Kim, S; Lembo, A; Pimentel, M; Shah, E, 2012) |
| " The goal of this review is to discern IBS treatment gaps and identify opportunities for improving its management in the primary care setting, as well as describe the most current clinical experience with alosetron, a targeted treatment for severe diarrhea-predominant IBS (IBS-D) in women." | 4.87 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. ( Bleser, S, 2011) |
| "Ischemic colitis and serious complications of constipation have been reported in association with the use of alosetron, which is approved for women with severe diarrhea-predominant IBS who have failed conventional therapies." | 4.83 | Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. ( Chang, L; Chey, WD; Harris, L; Olden, K; Schoenfeld, P; Surawicz, C, 2006) |
| "Alosetron (Lotronex, GlaxoSmithKline) is a potent and selective 5-HT(3)-receptor antagonist approved by the FDA for the treatment of women with diarrhoea-predominant irritable bowel syndrome (IBS) in whom conventional therapy has failed." | 4.82 | Alosetron and irritable bowel syndrome. ( Bradesi, S; Mayer, EA, 2003) |
| " Problems have arisen with alosetron being associated with ischaemic colitis and a high incidence of constipation." | 4.81 | Pharmacological treatment of irritable bowel syndrome--from concept to sales. ( Kamm, MA, 2002) |
| "More than one decade ago, rising cases of ischemic colitis (IC) prompted the Federal Drug Administration to revoke alosetron's approval as treatment of irritable bowel syndrome (IBS)." | 3.83 | Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. ( Bielefeldt, K, 2016) |
| "This article evaluates the characteristics and treatment patterns of female patients with severe diarrhea-predominant irritable bowel syndrome (IBS-D) who were treated with alosetron under a risk management program." | 3.78 | Evaluation of treatment continuation with alosetron by IBS-D severity criteria. ( Chuang, E; Nicandro, JP; Shin, P, 2012) |
| "Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP)." | 3.76 | Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. ( Ameen, V; Chang, L; Tong, K, 2010) |
| "Alosetron was reintroduced for treatment of irritable bowel syndrome with a risk management programme in November 2002." | 3.74 | The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. ( Andrews, E; Cook, S; Hickman, P; Hollis, K; Miller, D; Tennis, P, 2007) |
| " Gastroenterologists and their patients have been affected adversely by removal from the marketplace of two licensed agents for irritable bowel syndrome (IBS): alosetron and tegaserod." | 3.74 | Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. ( Johnson, DA; Schiller, LR, 2008) |
| "We examined the pharmacological profile of ramosetron, a 5-HT(3)-receptor antagonist for irritable bowel syndrome with diarrhea, comparing it with those of other 5-HT(3)-receptor antagonists, alosetron and cilansetron, and the anti-diarrheal agent loperamide." | 3.74 | Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M, 2007) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 3.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| "Alosetron hydrochloride (Lotronex, GlaxoSmithKline, Inc) is a safe and effective agent for selective patients with severe irritable bowel syndrome when prescribed as recommended." | 3.73 | Acute hepatitis associated with alosetron (Lotronex). ( Fontana, RJ; Tayeh, N; Turgeon, DK, 2005) |
| "In November 2002, alosetron HCl (Lotronex, GlaxoSmithKline Research Triangle Park, NC, USA) was re-introduced to the US marketplace for women with severe diarrhoea-predominant irritable bowel syndrome." | 3.73 | A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. ( Andrews, E; Bennett, L; Cook, S; Hollis, K; Miller, D; Tennis, P, 2006) |
| " The present study examines the binding profile of platelet SERT in healthy volunteers as well as in patients with diarrhea-predominant irritable bowel syndrome (D-IBS), both before and after treatment with the 5-HT(3) receptor antagonist alosetron." | 3.72 | Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. ( Baroni, S; Bellini, M; Betti, L; Blandizzi, C; Colucci, R; Costa, F; Del Tacca, M; Giannaccini, G; Marazziti, D; Marchi, S; Mumolo, MG; Rappelli, L; Stasi, C, 2003) |
| "Alosetron vs placebo treatments, in a randomized, double-blinded, crossover manner, were studied." | 2.71 | The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. ( D'Souza, D; Diksic, M; Kersey, K; Kumakura, Y; Nakai, A, 2005) |
| "Irritable bowel syndrome is categorized into one of three main categories: IBS with diarrhea, IBS with constipation, and IBS with mixed bowel habits." | 2.53 | Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. ( Lacy, BE, 2016) |
| "Alosetron was not associated with any deaths." | 2.44 | Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. ( Abdollahi, M; Nikfar, S; Rahimi, R, 2008) |
| "The etiology of irritable bowel syndrome is considered to be multifactorial: experimental and clinical research on visceral hypersensitivity, motility and brain-gut axis involving its neurotransmitters and receptors created the foundation of novel therapeutic approaches." | 2.44 | [Novel therapeutic approaches in the treatment of irritable bowel syndrome]. ( Herszényi, L; Juhász, M; Miheller, P; Pregun, I; Tulassay, Z, 2007) |
| "Alosetron is a potent and highly selective serotonin 5-HT(3 )receptor antagonist that in large randomised controlled clinical trials has been shown to be clinically efficient in female patients with diarrhoea-predominant IBS." | 2.42 | Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? ( Andresen, V; Hollerbach, S, 2004) |
| "Alosetron was also efficacious in stress-induced defecation and visceral pain models at 1 and 10 mg/kg, respectively." | 1.56 | Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron. ( Aso, K; Itomi, Y; Kawamura, T; Kojima, T; Matsumoto-Okano, S; Matsushita, K; Tanaka, T; Tsukimi, Y, 2020) |
| " Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported." | 1.51 | Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. ( Chey, WD; Chuang, E; Earnest, DL; Olden, KW; Paul Nicandro, J; Shringarpure, R, 2019) |
| "Visceral pain was measured by visceromotor response to colorectal distension, and the effects of alosetron and duloxetine on visceral pain were investigated in SART rats." | 1.42 | Specific alteration of rhythm in temperature-stressed rats possess features of abdominal pain in IBS patients. ( Itomi, Y; Kawamura, T; Tsukimi, Y, 2015) |
| "Irritable bowel syndrome affects 5-10% of North Americans, with an estimated one-third having a diarrhea-predominant form." | 1.36 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. ( Lewis, JH, 2010) |
| "WA stress led to visceral hyperalgesia 24 h later." | 1.34 | Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia. ( Bradesi, S; Hicks, GA; Lao, L; Lee, K; Mayer, EA; McLean, PG; Winchester, WJ, 2007) |
| "Because the mechanism(s) of drug-induced ischemic colitis and possibly other forms of intestinal ischemia associated with alosetron have not been elucidated, there is need to further assess risk with regard to patient susceptibility and other factors." | 1.33 | Alosetron: ischemic colitis and serious complications of constipation. ( Avigan, M; Brinker, A; Gallo-Torres, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (58.21) | 29.6817 |
| 2010's | 25 (37.31) | 24.3611 |
| 2020's | 3 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Asagarasu, A | 1 |
| Matsui, T | 1 |
| Hayashi, H | 1 |
| Tamaoki, S | 1 |
| Yamauchi, Y | 1 |
| Minato, K | 1 |
| Sato, M | 1 |
| Manning, DD | 2 |
| Cioffi, CL | 1 |
| Usyatinsky, A | 1 |
| Fitzpatrick, K | 1 |
| Masih, L | 2 |
| Guo, C | 2 |
| Zhang, Z | 2 |
| Choo, SH | 2 |
| Sikkander, MI | 1 |
| Ryan, KN | 2 |
| Naginskaya, J | 2 |
| Hassler, C | 1 |
| Dobritsa, S | 1 |
| Wierschke, JD | 2 |
| Earley, WG | 2 |
| Butler, AS | 1 |
| Brady, CA | 2 |
| Barnes, NM | 2 |
| Cohen, ML | 1 |
| Guzzo, PR | 2 |
| Newman, AS | 1 |
| Brenner, DM | 1 |
| Sayuk, GS | 1 |
| Itomi, Y | 2 |
| Tanaka, T | 1 |
| Matsushita, K | 1 |
| Kawamura, T | 2 |
| Kojima, T | 1 |
| Aso, K | 1 |
| Matsumoto-Okano, S | 1 |
| Tsukimi, Y | 2 |
| Chen, M | 1 |
| Tang, TC | 1 |
| Qin, D | 1 |
| Yue, L | 1 |
| Zheng, H | 1 |
| Olden, KW | 2 |
| Chey, WD | 5 |
| Shringarpure, R | 2 |
| Paul Nicandro, J | 1 |
| Chuang, E | 3 |
| Earnest, DL | 2 |
| El-Ayache, N | 1 |
| Galligan, JJ | 1 |
| Nee, J | 1 |
| Zakari, M | 1 |
| Lembo, AJ | 2 |
| Cash, BD | 2 |
| Lacy, BE | 4 |
| Rao, T | 1 |
| Bielefeldt, K | 1 |
| Dance, A | 1 |
| Morgan, B | 1 |
| Moreau, JC | 1 |
| Talley, NJ | 1 |
| Rahimi, R | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Jarcho, JM | 1 |
| Chang, L | 4 |
| Berman, M | 1 |
| Suyenobu, B | 1 |
| Naliboff, BD | 1 |
| Lieberman, MD | 1 |
| Ameen, VZ | 4 |
| Mandelkern, MA | 1 |
| Mayer, EA | 5 |
| Ford, AC | 1 |
| Brandt, LJ | 1 |
| Young, C | 1 |
| Foxx-Orenstein, AE | 1 |
| Moayyedi, P | 1 |
| Lewis, JH | 2 |
| Tong, K | 1 |
| Ameen, V | 2 |
| Bleser, S | 1 |
| Saad, RJ | 1 |
| Mönnikes, H | 1 |
| Nicandro, JP | 2 |
| Shin, P | 1 |
| Shah, E | 1 |
| Kim, S | 1 |
| Chong, K | 1 |
| Lembo, A | 3 |
| Pimentel, M | 2 |
| Kim, SE | 1 |
| Kubomoto, S | 1 |
| Chua, K | 1 |
| Amichai, MM | 1 |
| Cremonini, F | 1 |
| Atkinson, V | 1 |
| Ervin, CM | 1 |
| Mangel, AW | 2 |
| Scherl, E | 1 |
| Frissora, CL | 1 |
| Weber, HC | 1 |
| Farraye, FA | 1 |
| Bradesi, S | 2 |
| Bellini, M | 1 |
| Rappelli, L | 1 |
| Blandizzi, C | 1 |
| Costa, F | 1 |
| Stasi, C | 1 |
| Colucci, R | 1 |
| Giannaccini, G | 1 |
| Marazziti, D | 1 |
| Betti, L | 1 |
| Baroni, S | 1 |
| Mumolo, MG | 1 |
| Marchi, S | 1 |
| Del Tacca, M | 1 |
| Andresen, V | 2 |
| Hollerbach, S | 1 |
| Gordon, SL | 1 |
| Heath, AT | 3 |
| Carter, EG | 4 |
| Chey, WY | 1 |
| Dukes, GE | 2 |
| Northcutt, A | 1 |
| Johanson, JF | 1 |
| Kennedy, T | 1 |
| Rubin, G | 1 |
| Jones, R | 1 |
| McSorley, DJ | 1 |
| Ehrenpreis, ED | 1 |
| Nakai, A | 1 |
| Diksic, M | 1 |
| Kumakura, Y | 1 |
| D'Souza, D | 1 |
| Kersey, K | 1 |
| Kawano, K | 1 |
| Mori, T | 1 |
| Fu, L | 1 |
| Ito, T | 1 |
| Niisato, T | 1 |
| Yoshida, S | 1 |
| Shiokawa, S | 1 |
| Sato, Y | 1 |
| Murakami, H | 1 |
| Shishikura, T | 1 |
| Turgeon, DK | 1 |
| Tayeh, N | 1 |
| Fontana, RJ | 1 |
| Ismail, IM | 1 |
| Andrew, PD | 1 |
| Cholerton, J | 1 |
| Roberts, AD | 1 |
| Dear, GJ | 1 |
| Taylor, S | 1 |
| Koch, KM | 1 |
| Saynor, DA | 1 |
| Kamm, MA | 1 |
| Harris, L | 1 |
| Olden, K | 1 |
| Surawicz, C | 1 |
| Schoenfeld, P | 1 |
| Gallo-Torres, H | 1 |
| Brinker, A | 1 |
| Avigan, M | 1 |
| Komoto, S | 1 |
| Miura, S | 1 |
| Miller, D | 2 |
| Bennett, L | 1 |
| Hollis, K | 2 |
| Tennis, P | 2 |
| Cook, S | 2 |
| Andrews, E | 2 |
| Lao, L | 1 |
| McLean, PG | 1 |
| Winchester, WJ | 1 |
| Lee, K | 1 |
| Hicks, GA | 1 |
| Podovei, M | 1 |
| Kuo, B | 1 |
| Hickman, P | 1 |
| Mearin, F | 1 |
| Krause, R | 1 |
| Gordon, SH | 1 |
| West, M | 1 |
| Perschy, T | 1 |
| Pregun, I | 1 |
| Herszényi, L | 1 |
| Juhász, M | 1 |
| Miheller, P | 1 |
| Tulassay, Z | 1 |
| Hirata, T | 2 |
| Keto, Y | 2 |
| Funatsu, T | 2 |
| Akuzawa, S | 2 |
| Sasamata, M | 2 |
| Takeuchi, A | 1 |
| Montori, VM | 1 |
| Keller, J | 1 |
| West, CP | 1 |
| Layer, P | 1 |
| Camilleri, M | 1 |
| Schiller, LR | 1 |
| Johnson, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome[NCT03462966] | Phase 2 | 4 participants (Actual) | Interventional | 2018-07-01 | Terminated (stopped due to recruitment challenges) | ||
| Crossover Trial of Gluten and Gluten With Amylase-trypsin Inhibitors as Triggers of Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome[NCT03664531] | 34 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| Confocal Endomicroscopy Utility for Diagnosing Mucosa Micro-inflammation in Patients With Irritable Bowel Syndrome[NCT02651532] | 74 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | Millimetre of mercury (Mean) |
|---|---|
| Therapeutic | 106 |
A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | volume cubic centimeter (Mean) |
|---|---|
| Therapeutic | 37.5 |
"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin
| Intervention | Participants (Count of Participants) |
|---|---|
| Therapeutic | 2 |
29 reviews available for alosetron and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Topics: Adult; Carbolines; Diarrhea; Female; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel Sy | 2020 |
Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review.
Topics: Carbolines; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Irritable Bowel Syndrome; | 2020 |
Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Hum | 2015 |
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Topics: Abdominal Pain; Anti-Bacterial Agents; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidaz | 2016 |
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Topics: Antidiarrheals; Carbolines; Diarrhea; Gastrointestinal Agents; Humans; Imidazoles; Irritable Bowel S | 2016 |
Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
Topics: Carbolines; Diarrhea; Disease Management; Humans; Imidazoles; Irritable Bowel Syndrome; Parasympatho | 2016 |
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Topics: Carbolines; Female; Humans; Irritable Bowel Syndrome; Male; Randomized Controlled Trials as Topic; S | 2008 |
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Topics: Adult; Age Factors; Aged; Carbazoles; Carbolines; Dose-Response Relationship, Drug; Drug Administrat | 2009 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Topics: Carbolines; Cost of Illness; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel Synd | 2011 |
Peripherally acting therapies for the treatment of irritable bowel syndrome.
Topics: Alprostadil; Antidiarrheals; Carbolines; Dietary Fiber; Dietary Supplements; Gastrointestinal Agents | 2011 |
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Topics: Animals; Carbolines; Colitis, Ischemic; Female; Humans; Indoles; Irritable Bowel Syndrome; Male; Ser | 2011 |
Quality of life in patients with irritable bowel syndrome.
Topics: Aged; Carbolines; Constipation; Diarrhea; Female; Gastrointestinal Agents; Health Status; Humans; Ir | 2011 |
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Topics: Alprostadil; Antidepressive Agents, Tricyclic; Carbolines; Constipation; Diarrhea; Gastrointestinal | 2012 |
Clinical trials in irritable bowel syndrome: a review.
Topics: Alprostadil; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbolines; Do | 2013 |
Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Topics: Carbolines; Clinical Trials as Topic; Contraindications; Female; Gastrointestinal Agents; Humans; Ir | 2003 |
Alosetron and irritable bowel syndrome.
Topics: Carbolines; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Pain; Product Surveillance, P | 2003 |
Advances in the management of irritable bowel syndrome.
Topics: Antidepressive Agents, Tricyclic; Carbolines; Cost of Illness; Desipramine; Evidence-Based Medicine; | 2003 |
Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
Topics: Carbolines; Contraindications; Humans; Irritable Bowel Syndrome; Product Surveillance, Postmarketing | 2004 |
Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
Topics: Animals; Antidepressive Agents; Antidiarrheals; Carbolines; Cathartics; Humans; Indoles; Intestines; | 2004 |
Irritable bowel syndrome.
Topics: Adult; Aged; Antidepressive Agents; Carbolines; Dietary Fiber; Female; Gastrointestinal Agents; Huma | 2004 |
Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.
Topics: Aged; Carbolines; Diagnosis, Differential; Gastrointestinal Agents; Humans; Indoles; Irritable Bowel | 2005 |
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Topics: Antidepressive Agents; Benzofurans; Carbolines; Cisapride; Constipation; Drug Industry; Gastrointest | 2002 |
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
Topics: Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Constipation; Diarrhea; Female; Gastrointes | 2006 |
[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Topics: Carbazoles; Carbolines; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Male; Pyr | 2006 |
Irritable bowel syndrome: a practical review.
Topics: Antidepressive Agents; Carbolines; Dietary Fiber; Food Hypersensitivity; Gastrointestinal Agents; Ga | 2006 |
[Drug treatment of irritable bowel syndrome: an unmet need].
Topics: Abdominal Pain; Analgesics; Antidepressive Agents, Tricyclic; Antidiarrheals; Carbolines; Controlled | 2007 |
[Novel therapeutic approaches in the treatment of irritable bowel syndrome].
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Anti-Bacterial Agents; Antidepressive Agents; Carboli | 2007 |
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Carbazoles; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, Dr | 2008 |
Clinical practice. Irritable bowel syndrome.
Topics: Adult; Antidepressive Agents, Tricyclic; Carbolines; Cognitive Behavioral Therapy; Desipramine; Fema | 2008 |
7 trials available for alosetron and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.
Topics: Adult; Brain; Carbolines; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Male; Pilot | 2008 |
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
Topics: Activities of Daily Living; Adult; Carbolines; Constipation; Diarrhea; Dose-Response Relationship, D | 2012 |
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Topics: Adult; Carbolines; Constipation; Defecation; Diarrhea; Female; Gastrointestinal Agents; Humans; Irri | 2004 |
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Abdominal Pain; Carbolines; Chronic Disease; Diarrhea; Double-Blind Method; Female; Gastrointestinal | 2004 |
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Carbolines; Diarrhea; Dose-Response Relationship, Dr | 2005 |
The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.
Topics: Brain; Carbolines; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Male; Positron | 2005 |
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Topics: Carbolines; Constipation; Diarrhea; Double-Blind Method; Drug Tolerance; Female; Gastrointestinal Ag | 2007 |
31 other studies available for alosetron and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Topics: Administration, Oral; Animals; Biological Availability; Brain; Cell Line; Cricetinae; Cricetulus; Gu | 2010 |
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; M | 2011 |
The discovery of diazepinone-based 5-HT3 receptor partial agonists.
Topics: Administration, Oral; Animals; Azepines; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2014 |
Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron.
Topics: Adrenocorticotropic Hormone; Animals; Carbolines; Conditioning, Classical; Defecation; Disease Model | 2020 |
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Aged; Carbolines; Diarrhea; Female; Health Resources; Humans; Imidazoles; Irritable Bowel Syn | 2019 |
5-HT
Topics: Animals; Carbolines; Disease Models, Animal; Humans; Hyperalgesia; Hypersensitivity; Irritable Bowel | 2019 |
Specific alteration of rhythm in temperature-stressed rats possess features of abdominal pain in IBS patients.
Topics: Abdominal Pain; Animals; Carbolines; Cold Temperature; Disease Models, Animal; Duloxetine Hydrochlor | 2015 |
Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |
Transit time.
Topics: Anti-Bacterial Agents; Biofeedback, Psychology; Carbolines; Colitis; Diet; Dysentery; Dyspepsia; Egy | 2016 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; C | 2016 |
Board Review Vignette: Irritable Bowel Syndrome.
Topics: Abdominal Pain; Adult; Anion Exchange Resins; Antidiarrheals; Carbolines; Cholestyramine Resin; Cons | 2016 |
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Topics: Carbolines; Colitis, Ischemic; Constipation; Diarrhea; Dose-Response Relationship, Drug; Female; Hum | 2010 |
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Colitis, Ischemic; Constipation; Female; Humans | 2010 |
Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
Topics: Adolescent; Adult; Aged; Carbolines; Diarrhea; Fecal Incontinence; Female; Follow-Up Studies; Gastro | 2012 |
"Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials.
Topics: Adult; Carbolines; Desipramine; Diarrhea; Female; Gastrointestinal Agents; Humans; Irritable Bowel S | 2012 |
Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.
Topics: Carbolines; Carrier Proteins; Enteric Nervous System; Gastrointestinal Agents; Humans; Irritable Bow | 2003 |
Study design issues in irritable bowel syndrome.
Topics: Carbolines; Double-Blind Method; Gastrointestinal Agents; Humans; Indoles; Irritable Bowel Syndrome; | 2004 |
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Topics: Adult; Aged; Blood Platelets; Carbolines; Carrier Proteins; Diarrhea; Female; Humans; Irritable Bowe | 2003 |
New options for soothing an irritable bowel.
Topics: Carbolines; Diet; Dietary Fiber; Gastrointestinal Agents; Humans; Indoles; Irritable Bowel Syndrome; | 2004 |
Therapy for irritable bowel syndrome.
Topics: Carbolines; Humans; Indoles; Irritable Bowel Syndrome; Polypharmacy; Serotonin 5-HT3 Receptor Antago | 2004 |
New drug for bothersome bowels.
Topics: Carbolines; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome | 2000 |
Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
Topics: Animals; Carbolines; Constipation; Diarrhea; Dogs; Gastrointestinal Motility; Gastrointestinal Tract | 2005 |
Acute hepatitis associated with alosetron (Lotronex).
Topics: Adult; Biopsy; Carbolines; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; | 2005 |
Characterization of the metabolites of alosetron in experimental animals and human.
Topics: Animals; Carbolines; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dogs; Female; Gas | 2005 |
Alosetron: ischemic colitis and serious complications of constipation.
Topics: Carbolines; Colitis, Ischemic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndro | 2006 |
A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.
Topics: Adolescent; Adult; Aged; Carbolines; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Irr | 2006 |
Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia.
Topics: Acute Disease; Analgesics, Non-Narcotic; Animals; Avoidance Learning; Capsaicin; Carbolines; Cathete | 2007 |
The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme.
Topics: Adult; Aged; Carbolines; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Irritable Bowel | 2007 |
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Carbazoles; Carbolines; Carrier Proteins; Colon; Defecation; Gastrointestin | 2007 |
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Function | 2007 |
Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Drug Approval; Drug L | 2008 |